- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment...
Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene...
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues...
Award builds on company’s 23-year state partnership to accelerate better health outcomes for Medicaid membersMCLEAN, Va., Nov. 14, 2023 (GLOBE...
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate...
BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage...
Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office VisitSAN DIEGO, Nov. 14, 2023...
Phase 1 clinical study of GT-02287 initiated; dosing escalation on scheduleBETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics,...
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target...
SANTA CLARA, CA / ACCESSWIRE / November 13, 2023 / Zeto, Inc., an innovative EEG brain monitoring company, is excited...
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with...
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE...
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,...
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in...
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity...
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) --...
Psychedelic Science 2023 was the breakthrough conference in psychedelics over 5 days in June 2023 in Denver, CO. Hosted by...
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),...
Attributes 9,623% Revenue Growth to the exceptional clinical performance and unique technology of the Nalu Neurostimulation System in treating unmet...